Journal article
Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369.
Abstract
574
Background: Biomarkers of bone turnover, including urine N-telopeptide (uNTx) and serum C-telopeptide (sCTx) reflect tumor-related bone breakdown and have been used as surrogate measures of response to therapy in trials. Vascular endothelial growth factor (VEGF) levels correlate with extent of bone metastases (BM). We assessed whether vandetanib, an inhibitor of VEGF, epidermal growth factor receptor and RET signalling, …
Authors
Clemons MJ; Cochrane B; Califaretti N; Chia SKL; Dent RA; Song X; Robidoux A; Pond GR; Parpia S; Pritchard KI
Journal
Journal of Clinical Oncology, Vol. 31, No. 15_suppl, pp. 574–574
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2013
DOI
10.1200/jco.2013.31.15_suppl.574
ISSN
0732-183X